Tapentadol 100mg

What Is Tapentadol?

Tapentadol is a centrally acting synthetic analgesic belonging to the opioid (narcotic) class of medicines. In Australia, it is marketed primarily under the brand name Palexia IR and is classified as a Schedule 8 (S8) controlled drug, meaning it can only be obtained with a valid prescription from an authorised healthcare professional.

The medication is available in immediate-release film-coated tablets in strengths of 50 mg, 75 mg, and 100 mg of tapentadol (as hydrochloride). Extended-release formulations (such as Palexia SR or Tapaday 200 mg) are also available in some markets, providing prolonged pain control for chronic conditions.

Tapentadol is indicated for:

• Acute pain severe enough to require opioid analgesia when alternative treatments are ineffective or not tolerated (e.g., post-surgical pain).
• Chronic pain management, including neuropathic pain such as diabetic peripheral neuropathy and chronic lower back pain, when continuous opioid treatment is necessary.

How Tapentadol Works: Dual Mechanism of Action

What sets tapentadol apart from classical opioids like morphine or oxycodone is its dual mechanism of action within a single molecule.This unique pharmacological profile contributes to its analgesic efficacy while potentially reducing certain opioid-related side effects.

1. Mu-Opioid Receptor (MOR) Agonism

Tapentadol binds selectively to mu-opioid receptors in the brain, spinal cord, and peripheral tissues.Activation of these receptors inhibits the ascending pain pathway, reducing the perception of pain.However, tapentadol has a lower affinity for mu-opioid receptors compared to morphine (approximately 50-fold weaker), which may contribute to a reduced risk of certain opioid-associated adverse effects.

2. Norepinephrine (Noradrenaline) Reuptake Inhibition (NRI)

Tapentadol also inhibits the reuptake of norepinephrine at nerve terminals, increasing its concentration in the synaptic cleft. Elevated norepinephrine activates alpha-2-adrenergic receptors in the spinal cord and brain, enhancing the body's descending inhibitory pain pathways.This non-opioid mechanism provides additional analgesia, particularly beneficial in neuropathic pain states.

Synergistic Effect

The combination of these two mechanisms produces synergistic analgesia, meaning the pain-relieving effect is greater than what either mechanism would achieve alone. Clinical studies suggest that tapentadol provides analgesic efficacy equivalent to equipotent doses of oxycodone but with improved gastrointestinal tolerability (less nausea, vomiting, and constipation).

Tapentadol Dosage and Administration

Dosage must be individualised based on pain severity, prior analgesic experience, and patient response under close medical supervision.

Immediate-Release (IR) Tablets (e.g., Palexia IR, Tapentadol 50/75/100 mg)

• Starting dose: 50 mg to 100 mg every 4 to 6 hours as needed for pain.
• Day 1 titration: If pain control is inadequate, an additional dose may be taken as soon as 1 hour after the initial dose.
• Maintenance dosing: 50 mg, 75 mg, or 100 mg every 4 to 6 hours, adjusted to maintain adequate analgesia with acceptable tolerability.
• Maximum daily dose: Typically 700 mg on Day 1, then 600 mg/day thereafter for immediate-release formulations.

Extended-Release (ER) Tablets (e.g., Tapaday 200 mg, Palexia SR)

• Used for chronic pain requiring continuous, around-the-clock opioid treatment.
•  Dosing is usually once or twice daily, depending on the formulation.
•  Do not crush, chew, break, or dissolve extended-release tablets, as this can lead to rapid release of the entire dose, causing overdose and potentially fatal respiratory depression.

Special Populations

• Elderly patients: Start at the lower end of the dosing range and titrate slowly.
• Renal or hepatic impairment: Dose adjustment or avoidance may be necessary; consult prescribing information.
• Opioid-naïve patients: Begin with the lowest effective dose (50 mg) to minimise adverse effects.

Common Side Effects

Like all opioids, tapentadol can cause side effects, though its dual mechanism may result in a more favourable tolerability profile.

Very Common (may affect more than 1 in 10 people)

• Nausea (feeling sick)
• Constipation
• Dizziness
• Drowsiness (somnolence)
• Headache

Common (may affect up to 1 in 10 people)

• Vomiting
• Dry mouth
• Fatigue
• Loss of appetite
• Lightheadedness or fainting

Management Tips

• Constipation: Increase fluid and fibre intake; stool softeners or laxatives may be required.
• Dizziness/drowsiness: Avoid driving, operating machinery, or engaging in hazardous activities until you know how tapentadol affects you.
• Nausea: Taking the medication with food may help; antiemetics can be prescribed if needed.

Most side effects are mild to moderate and tend to diminish with continued use as the body adjusts. However, if side effects persist or become bothersome, consult your doctor.

Drug Interactions

Tapentadol can interact dangerously with other medications and substances.

CNS Depressants (Increased Risk of Sedation and Respiratory Depression)

• Alcohol: Avoid completely. Concurrent use can cause profound sedation, respiratory depression, coma, or death.
• Benzodiazepines (e.g., diazepam, alprazolam)
• Other opioids or opioid-containing products
• Sedatives/hypnotics (sleeping pills)
• Tranquillisers or muscle relaxants
•  Antihistamines with sedative properties

Serotonergic Drugs (Risk of Serotonin Syndrome)

Tapentadol's norepinephrine reuptake inhibition may increase serotonin levels. Combining with other serotonergic agents can precipitate serotonin syndrome, a potentially life-threatening condition. Symptoms include agitation, hallucinations, rapid heart rate, fever, muscle rigidity, nausea, vomiting, and diarrhoea. Seek immediate medical attention if these occur.

Drugs that increase serotonin risk:

• SSRIs/SNRIs (antidepressants like fluoxetine, venlafaxine)
• Tricyclic antidepressants (TCAs)
• Triptans (migraine medications)
• Certain antiemetics (e.g., ondansetron)
• Fentanyl, tramadol, methadone
• St John's Wort (herbal supplement)

MAO Inhibitors (Contraindicated)

As noted above, tapentadol must not be used with MAOIs (e.g., phenelzine, tranylcypromine, linezolid) due to the risk of severe hypertensive reactions.

Anticholinergic Drugs

May increase the risk of urinary retention and severe constipation.

Always inform your doctor and pharmacist of all medications, supplements, and herbal products you are taking before starting tapentadol.

Patient Considerations and Monitoring

Before Starting Tapentadol

Discuss the following with your healthcare provider:

• History of substance abuse, alcoholism, or mental health conditions (e.g., depression, anxiety)
• Breathing problems (asthma, COPD, sleep apnoea)
• Liver or kidney disease
• Seizure disorder or head injury
• Current medications (including over-the-counter drugs and supplements)
• Pregnancy, breastfeeding, or plans to conceive

During Treatment

• Regular follow-ups: Your doctor will monitor pain control, side effects, and signs of misuse or dependence.
• Do not stop abruptly: Sudden discontinuation after prolonged use can cause withdrawal symptoms (e.g., anxiety, sweating, insomnia, tremors). Tapering under medical supervision is required.
• Avoid alcohol and recreational drugs: These increase the risk of life-threatening side effects.
• Driving and machinery: Tapentadol can impair alertness and reaction time. Do not drive or operate heavy machinery until you know how the medication affects you.

Storage and Disposal

• Store in a secure, locked location out of reach of children and others for whom it is not prescribed.
• Dispose of unused tablets via a pharmacy take-back program or according to local regulations to prevent accidental ingestion or diversion.

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.